Position in DYN
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$19,414,604
+$4,514,482 QoQ
Shares Held
874,138
+6.4% QoQ
Ownership
0.468%
of shares outstanding
% of Portfolio
0.18%
of 13F equity value
Holder Rank
#44
of 245 holders
Holding Since
Dec 2024
7 quarters on record
Voting authority
Sole 35%
Shared 0%
None 65%
Common Shares in DYN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026FRONTIER CAPITAL MANAGEMENT CO LLC holds $975,847,387 across 22 Biotechnology names. DYN ranks #17 (2.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | BBIO |
BridgeBio Pharma, Inc.
|
1,373,057 | $102,265,285 | |
| 2 | RARE |
Ultragenyx Pharmaceutical Inc.
|
2,847,936 | $95,092,583 | |
| 3 | KYMR |
Kymera Therapeutics, Inc.
|
740,866 | $84,955,104 | |
| 4 | INSM |
INSMED Inc
|
795,242 | $84,788,702 | |
| 5 | PVLA |
Palvella Therapeutics, Inc.
|
478,833 | $73,175,259 | |
| 6 | JAZZ |
Jazz Pharmaceuticals plc
|
277,279 | $66,815,920 | |
| 7 | AXSM |
Axsome Therapeutics, Inc.
|
254,280 | $62,240,115 | |
| 8 | TRVI |
Trevi Therapeutics, Inc.
|
3,070,740 | $57,269,301 |
All Filings in DYN
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $19,414,604 | 874,138 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $14,900,122 | 821,849 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $22,276,258 | 1,138,868 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $11,523,125 | 910,919 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $7,515,326 | 789,425 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $3,029,247 | 289,603 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $7,022,105 | 298,052 | Shares | Sole | 2025-02-14 | |
| No filing history on record for this holder in this stock. | ||||||